Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life –– a double-blind, placebo-controlled study
Article first published online: 21 MAR 2011
© 2011 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 33, Issue 10, pages 1123–1132, May 2011
How to Cite
Guglielmetti, S., Mora, D., Gschwender, M. and Popp, K. (2011), Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life –– a double-blind, placebo-controlled study. Alimentary Pharmacology & Therapeutics, 33: 1123–1132. doi: 10.1111/j.1365-2036.2011.04633.x
- Issue published online: 13 APR 2011
- Article first published online: 21 MAR 2011
- Publication data Submitted 7 February 2011 First decision 22 February 2011 Resubmitted 1 March 2011 Accepted 1 March 2011 EV Pub Online 21 March 2011
Aliment Pharmacol Ther 2011; 33: 1123–1132
Background Recent research suggests that an imbalance of the intestinal microbiota and a dysfunctional intestinal barrier might trigger irritable bowel syndrome (IBS). As probiotics have been reported to restore the intestinal microbiota and the gut barrier, the therapeutic potential of probiotics within IBS became of strong interest.
Aim To assess the efficacy of Bifidobacterium bifidum MIMBb75 in IBS.
Methods A total of 122 patients were randomised to receive either placebo (N = 62) or MIMBb75 (N = 60) once a day for 4 weeks. The severity of IBS symptoms was recorded daily on a 7-point Likert scale.
Results MIMBb75 significantly reduced the global assessment of IBS symptoms by −0.88 points (95% CI: −1.07; −0.69) when compared with only −0.16 (95% CI: −0.32; 0.00) points in the placebo group (P < 0.0001). MIMBb75 also significantly improved the IBS symptoms pain/discomfort, distension/bloating, urgency and digestive disorder. The evaluation of the SF12 sum scores showed a significant gain in quality of life within the bifidobacteria group. Furthermore, adequate relief was reported by 47% of the patients in the bifidobacteria and only by 11% of the patients in the placebo group (P < 0.0001). Overall responder rates were 57% in the bifidobacteria group but only 21% in the placebo group (P = 0.0001). MIMBb75 was well tolerated and adverse events were not different from placebo.
Conclusions Bifidobacterium bifidum MIMBb75 effectively alleviates global IBS and improves IBS symptoms simultaneously with an improvement of quality of life. Considering the high efficacy of MIMBb75 in IBS along with the good side-effect profile, MIMBb75 is a promising candidate for IBS therapy.